Published in Am J Manag Care on February 01, 2017
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2010) 3.56
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation (2003) 3.22
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care (2003) 3.08
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care (2004) 3.00
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42
Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care (2010) 2.38
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet (2012) 2.13
Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf (2005) 2.00
Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care (2007) 1.95
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 1.83
Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care (2010) 1.78
Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics (2010) 1.70
Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol (2003) 1.70
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2013) 1.68
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes (2010) 1.60
Cardiovascular effects of insulin sensitizers in diabetes. Curr Opin Investig Drugs (2006) 1.55
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension (2005) 1.54
Beyond the monofilament for the insensate diabetic foot: a systematic review of randomized trials to prevent the occurrence of plantar foot ulcers in patients with diabetes. Diabetes Care (2011) 1.49
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care (2014) 1.47
Metabolic memory in diabetes--focus on insulin. Diabetes Metab Res Rev (2005) 1.43
ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS. Endocr Pract (2015) 1.39
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation (2014) 1.32
The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetes. Diabetes Care (2006) 1.31
Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications (2009) 1.26
Relationship between HbA1c level and peripheral arterial disease. Diabetes Care (2005) 1.20
Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities. Obesity (Silver Spring) (2010) 1.18
Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care (2012) 1.15
Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med (2004) 1.13
Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care (2006) 1.13
Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care (2013) 1.10
Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov (2009) 1.04
The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications (2012) 1.03
Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem (2010) 1.03
Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother (2012) 1.02
Translating the A1C Assay. Diabetes Care (2008) 1.00
Redefining the diagnosis of diabetes using glycated hemoglobin. Diabetes Care (2009) 1.00
Bile acid sequestrants for lipid and glucose control. Curr Diab Rep (2010) 0.96
Cardiovascular benefits of exogenous insulin. J Clin Endocrinol Metab (2012) 0.95
Differential association of birth weight with cardiovascular risk variables in African-Americans and Whites: the Bogalusa heart study. Ann Epidemiol (2004) 0.93
Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract (2008) 0.92
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 0.91
Management of diabetes mellitus in patients with cardiovascular disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2010) 0.90
Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications (2010) 0.88
Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin (2003) 0.87
Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Diabetes Care (2007) 0.87
Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs (2002) 0.87
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. Curr Diab Rep (2010) 0.87
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry (2009) 0.86
Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications (2008) 0.86
The effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on oxidative enzymes in adipocytes and liver. Toxicology (2002) 0.86
Racial disparity of eye examinations among the U.S. working-age population with diabetes: 2002-2009. Diabetes Care (2014) 0.84
Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf (2005) 0.84
Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. J Am Soc Hypertens (2009) 0.84
Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial database. J Manag Care Spec Pharm (2015) 0.83
The impact of antidiabetic therapies on cardiovascular disease. Curr Atheroscler Rep (2005) 0.83
The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care (2013) 0.82
Time to recovery in diabetes and comorbidities following Hurricane Katrina. Disaster Med Public Health Prep (2010) 0.82
Urinary catalytic iron in obesity. Clin Chem (2010) 0.82
Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol (2006) 0.82
Physician practice behavior and practice guidelines: using unannounced standardized patients to gather data. J Gen Intern Med (2008) 0.82
Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf (2012) 0.82
Economic burden of hypoglycemia in patients with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res (2012) 0.81
Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. Clin Chem (2010) 0.81
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care (2012) 0.81
Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord (2006) 0.79
Metabolic syndrome: underrated or underdiagnosed? Diabetes Care (2005) 0.79
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich) (2007) 0.79
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr (2008) 0.78
Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complications (2013) 0.78
ASSOCIATION BETWEEN HYPOGLYCEMIA AND FALL-RELATED FRACTURES AND HEALTH CARE UTILIZATION IN OLDER VETERANS WITH TYPE 2 DIABETES. Endocr Pract (2015) 0.78
Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. Diabetes Metab Syndr Obes (2009) 0.77
Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs (2002) 0.77
Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. Endocr Pract (2012) 0.77
Metabolic syndrome and heart failure. Heart Fail Clin (2006) 0.77
Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome. Curr Med Res Opin (2010) 0.77
Empirical derivation to improve the definition of the metabolic syndrome in the evaluation of cardiovascular disease risk. Diabetes Care (2011) 0.76
Comparing diabetes drugs--helping clinical decisions? Lancet (2012) 0.76
Case-based study: from prediabetes to complications--opportunities for prevention. PLoS Med (2005) 0.75
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: lessons for managing clinical trials during and after a natural disaster. Contemp Clin Trials (2008) 0.75
Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes. J Diabetes Complications (2013) 0.75
Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr (2008) 0.75
Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study. Pain Pract (2011) 0.75
REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES. Endocr Pract (2016) 0.75
Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". J Diabetes Complications (2017) 0.75
The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. Clin Transplant (2007) 0.75
The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications (2005) 0.75
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol (2012) 0.75
Diabetes: advances and controversies. Clin Chem (2010) 0.75
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord (2005) 0.75